To the full analysis
Johnson & Johnson stock: growth
JNJJohnson & Johnson reported $94.19B in revenue for fiscal 2025, up 6% on the prior year, up 6.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
3%
per year from 2006 to 2025, per share 4.1%
Earnings (Annual rate)
4.8%
per year from 2006 to 2025, per share 5.8%
Free cash flow (Annual rate)
2.9%
per year from 2006 to 2025, per share 3.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 2.7% | 3.0% | 3.0% |
| Revenue per share | 4.3% | 4.3% | 4.1% |
| Earnings | 12.7% | 5.7% | 4.8% |
| Earnings per share | 14.6% | 7.1% | 5.8% |
| Free cash flow | −0.5% | 2.2% | 2.9% |
| Free cash flow per share | 1.1% | 3.5% | 3.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $53.32B | $11.05B | $11.51B |
| 2007 | $61.1B | $10.58B | $11.94B |
| 2008 | $63.75B | $12.95B | $11.91B |
| 2009 | $61.9B | $12.27B | $14.21B |
| 2010 | $61.59B | $13.33B | $14B |
| 2011 | $65.03B | $9.67B | $11.41B |
| 2012 | $67.22B | $10.85B | $12.46B |
| 2013 | $71.31B | $13.83B | $13.82B |
| 2014 | $74.33B | $16.32B | $14.76B |
| 2015 | $70.07B | $15.41B | $15.82B |
| 2016 | $71.89B | $16.54B | $15.54B |
| 2017 | $76.45B | $1.3B | $17.78B |
| 2018 | $81.58B | $15.3B | $18.53B |
| 2019 | $82.06B | $15.12B | $19.92B |
| 2020 | $82.58B | $14.71B | $20.19B |
| 2021 | $78.74B | $20.88B | $19.76B |
| 2022 | $79.99B | $17.94B | $17.19B |
| 2023 | $85.16B | $35.15B | $18.25B |
| 2024 | $88.82B | $14.07B | $19.84B |
| 2025 | $94.19B | $26.8B | $19.7B |
Revenue by segment
How Johnson & Johnson makes its money and how that has shifted. Names are as the company reports them.
- Innovative Medicine64%
- MedTech36%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| Innovative Medicine | $54.76B | $56.96B | $60.4B | 64.1% |
| MedTech | $30.4B | $31.86B | $33.79B | 35.9% |
| Total revenue | $85.16B | $88.82B | $94.19B | 100% |
Revenue by region
Where Johnson & Johnson generates its revenue.
- United States57%
- Europe23%
- Asia Pacific and Africa15%
- Americas excluding US5%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| United States | $46.44B | $50.3B | $53.75B | 57.1% |
| Europe | $20.41B | $20.21B | $21.54B | 22.9% |
| Asia Pacific and Africa | $13.76B | $13.59B | $14.03B | 14.9% |
| Americas excluding US | $4.55B | $4.71B | $4.88B | 5.2% |
| Total revenue | $85.16B | $88.82B | $94.19B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 28 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.